Company Profile
Profil emiten IDX — keuangan, direksi, komisaris, anak usaha
PT UBC Medical Indonesia Tbk
LABS
Sector: Healthcare
Industry: Healthcare Equipment & Supplies
Sub Sector: Healthcare Equipment & Providers
Sub Industry: Healthcare Supplies & Distributions
Live quote
tidak tersedia
Highlight Keuangan (2026 Q2) (In Rp)
EPS
2
ROE
5,41%
ROA
3,80%
Book Value
40
Net Income
4,24 M
Total Sales
95,22 M
Total Assets
223,35 M
DER
0.43x
Struktur Pemegang Saham (>1%)
Free Float Information
Saham tersebar di publik
14,76%
Corporate · Lokal
Individual · Lokal
Individual · Lokal
3,29%
Individual · Lokal
Private Equity · Asing
Tentang Perusahaan
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Produk & Lini Bisnis
The Company main business activity is in the field of distributing medical devices. Wholesale Trade in Laboratory Equipment, Pharmaceutical Equipment and Medical Equipment for Humans, which includes wholesale trade in laboratory equipment, pharmaceutical equipment and medical equipment for humans, with the Standard Classification Code for Indonesian Business Fields (KBLI) 46691.
Dewan Direksi
FY
FX. Yoshua Raintjung
President Director
MA
Marcela Angelin
Director
Dewan Komisaris
NT
Nathan Tirtana
President Commissioner
S
Suyanto
Independent Commissioner
Anak Usaha & Afiliasi
NamaDomisili%
PT. Esora Medika Indonesia
Pharmaceutical industry, chemical products and traditional medicine
East Jakarta 99.99%
PT. Elion Medika Indonesia
Trading, health activity
South Jakarta 0.00%
Trend Keuangan (5 periode terakhir) — hover bar untuk detail
Total Sales Net Income (+) Net Income (-)
199jt 149jt 100jt 50jt 0 Sales 2025Q2: Rp 86.696.572 Net Income 2025Q2: Rp 7.057.204 2025Q2 Sales 2025Q3: Rp 135.436.066 Net Income 2025Q3: Rp 11.963.337 2025Q3 Sales 2025Q4: Rp 199.295.144 Net Income 2025Q4: Rp 13.506.777 2025Q4 Sales 2026Q1: Rp 40.021.864 Net Income 2026Q1: Rp 409.631 2026Q1 Sales 2026Q2: Rp 95.222.444 Net Income 2026Q2: Rp 4.240.325 2026Q2
2025 Q2
EPS 4
ROE 9,68%
2025 Q3
EPS 4
ROE 10,58%
2025 Q4
EPS 3
ROE 8,86%
2026 Q1
EPS 0
ROE 1,07%
2026 Q2
EPS 2
ROE 5,41%
Laporan Keuangan Historis (5 Periode Terakhir) (In Rp)
PeriodeTotal SalesNet IncomeTotal AssetsTotal EquityEPSROEDER
2026 Q2 95,22 M 4,24 M 223,35 M 156,70 M 2 5,41% 0.43x
2026 Q1 40,02 M 409,63 Jt 218,61 M 152,87 M 0 1,07% 0.43x
2025 Q4 199,30 M 13,51 M 228,19 M 152,46 M 3 8,86% 0.50x
2025 Q3 135,44 M 11,96 M 217,49 M 150,72 M 4 10,58% 0.44x
2025 Q2 86,70 M 7,06 M 209,16 M 145,81 M 4 9,68% 0.43x
History Harga Penutupan & Book Value
TahunQrtClose Price (Rp)Book Value (Rp)ROA
2026 2 135 40 3,80%
2026 1 157 39 0,75%
2025 4 137 39 5,92%
2025 3 141 38 7,33%
2025 2 136 37 6,75%
Data diperbarui pada: 2026-05-12 11:03:56